1. Ablation of a galectin preferentially expressed in adipocytes increases lipolysis, reduces adiposity, and improves insulin sensitivity in mice
- Author
-
Kevin C K Lloyd, Ri Yao Yang, James L. Graham, Peter J. Havel, Daniel K. Hsu, Fu-Tong Liu, and Lan Yu
- Subjects
medicine.medical_specialty ,Galectins ,Lipolysis ,medicine.medical_treatment ,Cell Cycle Proteins ,Mice, Transgenic ,Biology ,Mice ,chemistry.chemical_compound ,Insulin resistance ,Lectins ,Commentaries ,Adipocyte ,Lipid droplet ,Internal medicine ,Adipocytes ,Cyclic AMP ,medicine ,Animals ,Insulin ,Protein kinase A signaling ,Multidisciplinary ,Phosphoric Diester Hydrolases ,Lipid metabolism ,3T3 Cells ,Lipid Metabolism ,medicine.disease ,Cyclic AMP-Dependent Protein Kinases ,Endocrinology ,chemistry ,Insulin Resistance ,Signal Transduction ,Hormone - Abstract
The breakdown of triglycerides, or lipolysis, is a tightly controlled process that regulates fat mobilization in accord with an animal's energy needs. It is well established that lipolysis is stimulated by hormones that signal energy demand and is suppressed by the antilipolytic hormone insulin. However, much still remains to be learned about regulation of lipolysis by intracellular signaling pathways in adipocytes. Here we show that galectin-12, a member of a β-galactoside–binding lectin family preferentially expressed by adipocytes, functions as an intrinsic negative regulator of lipolysis. Galectin-12 is primarily localized on lipid droplets and regulates lipolytic protein kinase A signaling by acting upstream of phosphodiesterase activity to control cAMP levels. Ablation of galectin-12 in mice results in increased adipocyte mitochondrial respiration, reduced adiposity, and ameliorated insulin resistance/glucose intolerance. This study identifies unique properties of this intracellular galectin that is localized to an organelle and performs a critical function in lipid metabolism. These findings add to the significant functions exhibited by intracellular galectins, and have important therapeutic implications for human metabolic disorders.
- Published
- 2011
- Full Text
- View/download PDF